抗菌药物耐药负担研究测算方法现状与分析(5)
[11] DE KRAKER ME，WOLKEWITZ M，DAVEY PG，et al. Burden of antimicrobial resistance in European hospitals：excess mortality and length of hospital stay associated with bloodstream infections due to escherichia coli resistant to third-generation cephalosporins[J]. J Antimicrob Chemother，2011，66(2)：398-407.
[12] DE KRAKER ME，WOLKEWITZ M，DAVEY PG，et al. Clinical impact of antimicrobial resistance in European hospitals：excess mortality and length of hospital stay related to methicillin-resistant staphylococcus aureus bloodstream infections[J]. Antimicrob Agents Chemother，2011，55(4)：1598-1605.
, http://www.100md.com
[13] STEWARDSON AJ，FANKHAUSER C，DE ANGELIS G，et al. Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss university hospital and a nationwide predictive model[J]. Infect Control Hosp Epidemiol，2013，34(2)：133-143.
[14] WHO. WHO-Choice unit cost estimates for service delivery[EB/OL].(2011-08-01)[2017-06-18].http：//www.who.int/choice/country/WHO-CHOICEunit_cost_estimates_ 2007_2008.xls.
, http://www.100md.com
[15] LEE BY，SINGH A，DAVID MZ，et al. The economic burden of community-associated methicillin-resistant staphylococcus aureus (CA-MRSA)[J]. Clin Microbiol Infect，2013，19(6)：528-536.
[16] BARTSCH SM，MCKINNELL JA，MUELLER LE，et al. Potential economic burden of carbapenem-resistant enterobacteriaceae (CRE) in the United States[J]. Clin Microbiol Infect，2017.DOI：10.1016/j.cmi.2016.09.003.
[17] MARAGAKIS LL，PERENCEVICH EN，COSGROVE SE. Clinical and economic burden of antimicrobial resistance[J]. Anti Infect Ther，2008，6(5)：751-763.
, http://www.100md.com
[18] IBRAHIM EH，SHERMAN G，WARD S，et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting[J]. Chest，2000，118(1)：146-155.
[19] KIM CJ，KIM HB，OH MD，et al. The burden of nosocomial staphylococcus aureus bloodstream infection in South Korea：a prospective hospital-based nationwide study[J]. BMC Infect Dis，2014.DOI：10.1186/s12879-014- 0590-4.
[20] SCHULGEN G，KROPEC A，KAPPSTEIN I，et al. Estimation of extra hospital stay attributable to nosocomial infections：heterogeneity and timing of events[J]. J Clin Epidemiol，2000，53(4)：409-417.
[21] COSGROVE SE，KAYE KS，ELIOPOULOUS GM，et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in enterobacter species[J]. Arch Intern Med，2002，162(2)：185-190.
[22] MCCABE W，JACKSON G. Gram-negative bacteremia[J]. Arch Intern Med，1962，110(6)：847-855., 百拇医药(海沙尔江·吾守尔 魏国旭 管晓东 史录文)
[12] DE KRAKER ME，WOLKEWITZ M，DAVEY PG，et al. Clinical impact of antimicrobial resistance in European hospitals：excess mortality and length of hospital stay related to methicillin-resistant staphylococcus aureus bloodstream infections[J]. Antimicrob Agents Chemother，2011，55(4)：1598-1605.
, http://www.100md.com
[13] STEWARDSON AJ，FANKHAUSER C，DE ANGELIS G，et al. Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss university hospital and a nationwide predictive model[J]. Infect Control Hosp Epidemiol，2013，34(2)：133-143.
[14] WHO. WHO-Choice unit cost estimates for service delivery[EB/OL].(2011-08-01)[2017-06-18].http：//www.who.int/choice/country/WHO-CHOICEunit_cost_estimates_ 2007_2008.xls.
, http://www.100md.com
[15] LEE BY，SINGH A，DAVID MZ，et al. The economic burden of community-associated methicillin-resistant staphylococcus aureus (CA-MRSA)[J]. Clin Microbiol Infect，2013，19(6)：528-536.
[16] BARTSCH SM，MCKINNELL JA，MUELLER LE，et al. Potential economic burden of carbapenem-resistant enterobacteriaceae (CRE) in the United States[J]. Clin Microbiol Infect，2017.DOI：10.1016/j.cmi.2016.09.003.
[17] MARAGAKIS LL，PERENCEVICH EN，COSGROVE SE. Clinical and economic burden of antimicrobial resistance[J]. Anti Infect Ther，2008，6(5)：751-763.
, http://www.100md.com
[18] IBRAHIM EH，SHERMAN G，WARD S，et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting[J]. Chest，2000，118(1)：146-155.
[19] KIM CJ，KIM HB，OH MD，et al. The burden of nosocomial staphylococcus aureus bloodstream infection in South Korea：a prospective hospital-based nationwide study[J]. BMC Infect Dis，2014.DOI：10.1186/s12879-014- 0590-4.
[20] SCHULGEN G，KROPEC A，KAPPSTEIN I，et al. Estimation of extra hospital stay attributable to nosocomial infections：heterogeneity and timing of events[J]. J Clin Epidemiol，2000，53(4)：409-417.
[21] COSGROVE SE，KAYE KS，ELIOPOULOUS GM，et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in enterobacter species[J]. Arch Intern Med，2002，162(2)：185-190.
[22] MCCABE W，JACKSON G. Gram-negative bacteremia[J]. Arch Intern Med，1962，110(6)：847-855., 百拇医药(海沙尔江·吾守尔 魏国旭 管晓东 史录文)